Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) regarding their holdings in American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
Transaction Details:
- Transaction Date: July 11, 2013
- Price per ADS: $52.8088
- Transaction Type: Re-investment of dividends paid to shareholders.
Material Changes
The filing details increases in personal holdings for specific directors and connected persons resulting from dividend re-investment. No material changes to the company's financial position or operations are reported in this document.
- Dr M M Slaoui: 873.091 ADSs (Connected Person: Dr K Slaoui, 14.660 ADSs)
- Mrs D P Connelly: 453.032 ADSs
- Mr W C Louv: 78.910 ADSs
- Mr D E Troy: 267.285 ADSs
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Investor Verification Checklist
- Verify the total number of ADSs acquired by directors via dividend re-investment on July 11, 2013.
- Confirm the transaction price of $52.8088 per ADS against market data for the date.
- Review the company's annual report (Form 20-F) for comprehensive financial performance metrics not included in this 6-K.